This clinical trial studies how well magnetic resonance imaging (MRI) works in diagnosing prostate cancer in men at high risk of developing prostate cancer. An MRI exam is a procedure in which radio waves and powerful magnet linked to a computer are used to created detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. This trial may help researchers determine if early MRI screening can improve the detection of high-grade prostate cancer in men at high-risk of developing prostate cancer. This may improve the diagnosis and management for prostate cancer and outcomes for future patients.
Additional locations may be listed on ClinicalTrials.gov for NCT05608694.
Locations matching your search criteria
United States
Illinois
Chicago
University of Chicago Comprehensive Cancer CenterStatus: Active
Contact: Scott E. Eggener
Phone: 773-702-5195
Evanston
NorthShore University HealthSystemStatus: Active
Contact: Brian Todd Helfand
Phone: 847-503-3000
PRIMARY OBJECTIVE:
I. Determine whether MRI screening can improve the detection of high-grade prostate cancer in men at high-risk of developing prostate cancer.
SECONDARY OBJECTIVES:
I. Compare baseline prostate MR images of men at high risk of developing prostate cancer to those without an identifiable predisposition.
II. Evaluate the role of a genetic risk score (GRS) in screening men with at elevated risk of being diagnosed with prostate cancer.
OUTLINE:
Participants receive gadolinium intravenously (IV) and undergo MRI over 60 minutes every 3 years (or as clinically indicated) until a diagnosis of prostate cancer. Participants also undergo collection of blood and saliva samples for genetic testing on study.
Participants are followed for up to 15 years.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Chicago Comprehensive Cancer Center
Principal InvestigatorScott E. Eggener
